UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 284

Sortiert nach

Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer

The New England journal of medicine, 2019-06, Vol.380 (24), p.2382-2382

2019

Volltextzugriff (PDF)

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G

Cancer science, 2016-12, Vol.107 (12), p.1843-1850

2016

Volltextzugriff (PDF)

Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy‐Induced Nausea and Vomiting: A Systematic Review and Network Meta‐Analysis

The oncologist (Dayton, Ohio), 2019-06, Vol.24 (6), p.e347-e357

2019

Volltextzugriff (PDF)

The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition

Breast cancer (Tokyo, Japan), 2020-05, Vol.27 (3), p.322-331

2020

Volltextzugriff (PDF)

Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS)

Cancer science, 2022-09, Vol.113 (9), p.3169-3179

2022

Volltextzugriff (PDF)

Assessment of a cancer genomic profile test for patients with metastatic breast cancer

Scientific reports, 2022-03, Vol.12 (1), p.4813-4813, Article 4813

2022

Volltextzugriff (PDF)

Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy

Supportive care in cancer, 2015-04, Vol.23 (4), p.1137-1143

2015

Volltextzugriff (PDF)

Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B)

European journal of cancer (1990), 2022-08, Vol.171, p.193-202

2022

Volltextzugriff (PDF)

Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review

BMC cancer, 2019-10, Vol.19 (1), p.980-10, Article 980

2019

Volltextzugriff (PDF)

Prognostic value of programmed death‐ligand 1 expression in patients with stage III colorectal cancer

Cancer science, 2017-05, Vol.108 (5), p.853-858

2017

Volltextzugriff (PDF)

Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial

The lancet oncology, 2016, Vol.17 (1), p.90-98

2016

Volltextzugriff (PDF)

Transcriptomic intratumor heterogeneity of breast cancer patient-derived organoids may reflect the unique biological features of the tumor of origin

Breast cancer research : BCR, 2023-02, Vol.25 (1), p.21-21, Article 21

2023

Volltextzugriff (PDF)

Effectiveness of self-help workbook intervention on quality of life in cancer patients receiving chemotherapy: results of a randomized controlled trial

BMC cancer, 2021-05, Vol.21 (1), p.1-588, Article 588

2021

Volltextzugriff (PDF)

CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study

Journal of clinical oncology, 2020-02, Vol.38 (6), p.558-566

2020

Volltextzugriff (PDF)

Analysis of Adverse Events Associated with Trastuzumab Deruxtecan in Patients with Gastric and Breast Cancer: A Retrospective Study

Biological and Pharmaceutical Bulletin, 2024/02/10, Vol.47(2), pp.411-416

2024

Volltextzugriff (PDF)

Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2005-10, Vol.23 (28), p.6829-6837

2005

Volltextzugriff (PDF)

Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B)

Breast (Edinburgh), 2023-10, Vol.71, p.22-28

2023

Volltextzugriff (PDF)

EGFR Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in Japan

Journal of clinical oncology, 2008-12, Vol.26 (34), p.5589-5595

2008

Volltextzugriff (PDF)

A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer

Breast cancer research and treatment, 2020-02, Vol.180 (1), p.135-146

2020

Volltextzugriff (PDF)

Systemic therapy for metastatic breast cancer

Annals of oncology, 2019-10, Vol.30, p.vi61

Takano, Toshimi

2019

Volltextzugriff (PDF)

Phenotypical change of tumor-associated macrophages in metastatic lesions of clear cell renal cell carcinoma

Medical molecular morphology, 2018-03, Vol.51 (1), p.57-63

2018

Volltextzugriff (PDF)

Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients

BMC cancer, 2020-04, Vol.20 (1), p.325-7, Article 325

2020

Volltextzugriff (PDF)

Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2019-01, Vol.22 (1), p.155-163

2019

Volltextzugriff (PDF)

Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study

BMC cancer, 2022-01, Vol.22 (1), p.36-36, Article 36

2022

Volltextzugriff (PDF)

Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B)

BMJ open, 2023-04, Vol.13 (4), p.e070304-e070304

2023

Volltextzugriff (PDF)

1 – 25 von 284

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(265)
Mit Volltextzugriff
(274)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(144)
Life Sciences & Biomedicine
(143)
Oncology
(112)
Humans
(110)
Female
(79)
Breast Cancer
(64)
Chemotherapy
(59)
Medicine
(46)
Medicine & Public Health
(44)
Middle Aged
(43)
Cancer Research
(42)
Aged
(41)
Male
(38)
Patients
(38)
Surgical Oncology
(35)
Adult
(34)
Metastasis
(33)
Breast Neoplasms - Drug Therapy
(32)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(28)
Cancer Therapies
(28)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G

Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy‐Induced Nausea and Vomiting: A Systematic Review and Network Meta‐Analysis

The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition

Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS)

Assessment of a cancer genomic profile test for patients with metastatic breast cancer

Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy

Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B)

Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review

Prognostic value of programmed death‐ligand 1 expression in patients with stage III colorectal cancer

Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial

Transcriptomic intratumor heterogeneity of breast cancer patient-derived organoids may reflect the unique biological features of the tumor of origin

Effectiveness of self-help workbook intervention on quality of life in cancer patients receiving chemotherapy: results of a randomized controlled trial

CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study

Analysis of Adverse Events Associated with Trastuzumab Deruxtecan in Patients with Gastric and Breast Cancer: A Retrospective Study

Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer

Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B)

EGFR Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in Japan

A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer

Systemic therapy for metastatic breast cancer

Phenotypical change of tumor-associated macrophages in metastatic lesions of clear cell renal cell carcinoma

Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients

Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial

Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study

Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B)

Suchergebnisse filtern